SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Babe Didrikson Zaharias

PatientMildred Ella Didrikson Zaharias
Date of birth1984-06-26
IdentifiersMRN HR-ML038-SYN; SSN (made up) 000-38-4471
Document date2026-10-05
AuthorRosalind Vasquez-Thornbury, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Final restaging after nine doses of dostarlimab. [S]

History of Present Illness

Ms. Didrikson Zaharias returns two weeks after her ninth and last dose of dostarlimab. Final restaging last week showed only fibrosis on MRI, no metastases on CT, and a flat white scar with no ulcer on sigmoidoscopy. She has had no bleeding, urgency or change in bowel habit for five months, and no diarrhea, rash, cough or breathlessness. She takes levothyroxine 75 micrograms each morning, has no tiredness or cold intolerance, and is still taking ferrous sulfate. The second hepatitis B vaccine dose was given with the last dose of dostarlimab. She played four tournaments over the summer and won a regional event last month. She asked what watch-and-wait means and how she will know if the cancer comes back. [S]

ElementDetail
TreatmentNine doses of dostarlimab over six months, completed two weeks ago
RestagingMRI: complete response; CT: no metastases; sigmoidoscopy: flat white scar, no ulcer
Adverse eventsImmune-related hypothyroidism, replaced; nothing else
SportCompeting; won a regional event last month

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; weight 63.4 kg, steady
GastrointestinalNegativeNormal bowel movements; no bleeding, urgency or leakage
EndocrineNegativeNo cold intolerance or palpitations
GenitourinaryNegativeSex comfortable; no urinary symptoms
RespiratoryNegativeNo cough or breathlessness
PsychiatricNegativeRelieved; some worry before each scan; PHQ-9 2, GAD-7 3; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morningOne tablet every other morningOral route2026-03-30activeS
Dostarlimab-gxly 50 mg/mL injection, 500 mg intravenously over 30 minutes every 3 weeks, for nine doses (six months)500 mg every 3 weeks for nine dosesIntravenous route2026-04-06 to 2026-09-21completedS
Levothyroxine 75 microgram oral tablet, one tablet by mouth each morning on an empty stomach, four hours apart from ironOne tablet each morningOral route2026-06-29activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-05Body height168cmS
2026-10-05Body weight63.4kgS
2026-10-05Body mass index (BMI) [Ratio]22.5kg/m2S
2026-10-05Systolic blood pressure112mm[Hg]S
2026-10-05Diastolic blood pressure70mm[Hg]S
2026-10-05Heart rate64/minS
2026-10-05Respiratory rate14/minS
2026-10-05Body temperature36.6CelS
2026-10-05Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-05Hemoglobin [Mass/volume] in Blood13.4g/dL12-15.5 g/dLNormalS
2026-10-05MCV [Entitic mean volume] in Red Blood Cells by Automated count86fL80-100 fLNormalS
2026-10-05Leukocytes [#/volume] in Blood by Automated count6.110*3/uL4-11 10*3/uLNormalS
2026-10-05Platelets [#/volume] in Blood by Automated count25510*3/uL150-400 10*3/uLNormalS
2026-10-05Creatinine [Mass/volume] in Serum or Plasma0.77mg/dL0.59-1.04 mg/dLNormalS
2026-10-05Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M99mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-05Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L7-35 U/LNormalS
2026-10-05Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L8-35 U/LNormalS
2026-10-05Ferritin [Mass/volume] in Serum or Plasma41ng/mL15-150 ng/mLNormalS
2026-10-05Thyrotropin [Units/volume] in Serum or Plasma2.4m[IU]/L0.45-4.5 mIU/LNormalS
2026-10-05Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
2026-10-05Carcinoembryonic Ag [Mass/volume] in Serum or Plasma1.6ng/mLUp to 3.0 ng/mL in non-smokersNormalS
2026-10-05Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S
2026-10-05Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]3{score}S

Physical Exam

Vital signs recorded on 2026-10-05; see the Vital Signs section. [S]

SystemFinding
GeneralFit and well; weight 63.4 kg; blood pressure 112/70, pulse 64
NeckThyroid not enlarged
Lymph nodesNo inguinal or supraclavicular nodes
AbdomenSoft, non-tender; no liver enlargement or mass
RectalWith her agreement and a chaperone: smooth, supple wall; no mass, nodule or ulcer; normal sphincter tone; no blood

Problems

ProblemClinical statusVerificationCodeProvenance
Bright red blood with bowel movements for about three months, with narrower stools, urgency, a feeling of incomplete emptying, and a firm, ulcerated mass felt on the back wall of the lower rectum at about 5 cm from the anal verge: a rectal cancer must be confirmed or excluded. Colonoscopy with biopsy booked this weekresolvedconfirmed K62.5S — Synthetic presenting problem anchored to the documented fatigue before her cancer diagnosis. Superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic rectal blood loss: hemoglobin 11.0 g/dL, MCV 77 fL, ferritin 9 ng/mL, with tirednessactiveconfirmed D50.0S — Synthetic finding anchored to the documented fatigue at the end of the 1952 season.
Adenocarcinoma of the low rectum, mismatch repair deficient (loss of MSH2 and MSH6; microsatellite instability high), cT3bN1M0 (stage IIIB) on pelvic MRI, lower edge 4 cm from the anal verge and about 1 cm above the anorectal junction, mesorectal fascia clear, no extramural venous invasion; CEA 5.8 ng/mL; synthetic modern detail linked to her documented cancer, whose site the sources do not record exactlyactiveconfirmed C20S — Synthetic histology, site, stage, mismatch repair status and course; the sources say she had cancer treated with a colostomy and call it colon cancer (R on the site). See sources.md.
Acute viral upper respiratory infection with cough and sore throat, a week before cycle 4 of dostarlimab; oxygen saturation and chest X-ray normal, so immune-related pneumonitis is unlikely; rapid influenza and COVID-19 tests negative; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness; not a historical claim.
Immune-related primary hypothyroidism from dostarlimab, grade 2: tiredness and cold hands, TSH 12.6 mIU/L and free T4 0.6 ng/dL after four doses, following a mild TSH rise four weeks earlier; dostarlimab continuedactiveconfirmed E03.2S — Synthetic common immune-related adverse event of PD-1 blockade.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingFinal restaging pelvic MRI, CT of the chest, abdomen and pelvis, and flexible sigmoidoscopyAfter the last doseUp to dateLast week: complete response on MRI and endoscopy; no metastases on CT
ExaminationDigital rectal examinationAt each oncology visit during treatment; every three to four months in watch-and-waitCompleted todayNormal; no mass or ulcer
LaboratoryCEAAt diagnosis, at each restaging, then every three to six months for two yearsCompleted today1.6 ng/mL
LaboratoryBlood countAfter treatment and with surveillanceCompleted todayHemoglobin 13.4 g/dL, MCV 86 fL, white cells 6.1, platelets 255
LaboratoryFerritin after oral ironAbout three months after startingCompleted today41 ng/mL, drawn late (deviation recorded at the fourth visit)
LaboratoryKidney and liver functionAfter PD-1 blockadeCompleted todayCreatinine 0.77 mg/dL, eGFR 99; ALT 19, AST 21 U/L
LaboratoryTSH and free T4At baseline, then every six weeks on PD-1 blockade; six weeks after any levothyroxine changeCompleted todayTSH 2.4 mIU/L, free T4 1.2 ng/dL on levothyroxine 75 micrograms
LaboratoryTSH and free T4 with the ninth doseEvery six weeks on PD-1 blockadeDeferredMissed: the thyroid tests due with the ninth dose, six weeks after the preventive visit, were not on the infusion order. No harm resulted, since the TSH today, eight weeks after the last check, is in range on an unchanged dose; corrective action: thyroid tests added to her standing surveillance order set, and the infusion center's PD-1 order set reviewed so that thyroid tests repeat automatically every six weeks
ImagingPelvic MRI in watch-and-waitEvery six months for two to three yearsDueNext in six months
ImagingFlexible sigmoidoscopy in watch-and-waitEvery three to four months for two years, then every six months to five yearsDueNext in three months
ImagingCT of the chest, abdomen and pelvisEvery six to twelve months for five yearsDueNext in six to twelve months
ImagingColonoscopyAt one yearDueNext in one year
Self-managementSurvivorship care planWithin a year of completing treatmentCompleted todayWritten treatment summary, surveillance schedule and warning signs given to her
Self-managementBowel function (low anterior resection syndrome, incontinence)After rectal surgery or radiationNot indicatedNo surgery or radiation; bowel function normal
ReferralWound-ostomy nursingIf a stoma is createdNot indicatedNo stoma
Self-managementSexual function and fertilityThrough survivorshipCompleted todaySex comfortable; contraception continued for four months after the last dose; not planning a pregnancy
SurveyDistress and depression screen (PHQ-9, GAD-7)At diagnosis, at each treatment phase, and at least yearlyCompleted todayPHQ-9 2 (item 9 scored 0), GAD-7 3
Self-managementLifestyle: activity, diet and alcoholEach visitCompleted todayGolf and strength work most days; red meat cut back; alcohol rare

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026); Cercek A, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med 2025;392(23):2297-2308 (PMID 40293177) (2025); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Rex DK, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2017;112(7):1016-1030 (PMID 28555630) (2017); CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026)

Follow-up: Sigmoidoscopy and examination in three months; MRI in six months; primary care review in three months with TSH at six months. [S]